

1 **ISOLATION OF DENGUE SEROTYPE 3 VIRUS FROM THE CEREBROSPINAL**
2 **FLUID OF AN ENCEPHALITIS PATIENT IN HAI PHONG, VIETNAM IN 2013**

3

4 **Phu Ly Minh Huong^{1,2}, Yuki Takamatsu¹, Takeshi Nabeshima¹, Pham Hoai Linh Ly³,**
5 **Pham Thi Hang³, Dang Thi Dinh³, Nguyen Ngoc Linh⁴, Nguyen Thi Thu Thuy⁴, Le Thi**
6 **Quynh Mai⁴, Corazon C. Buerano¹, Kouichi Morita¹ and, Futoshi Hasebe^{1,5*}.**

7 1) Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki,
8 Japan

9 2) Graduate School of Biochemical Sciences, Nagasaki University, Nagasaki, Japan

10 3) NIHE-Nagasaki Friendship Laboratory, Nagasaki University, Hanoi, Vietnam

11 4) Department of Virology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

12 5) Center of International Collaborative Research, Nagasaki University, Nagasaki, Japan

13 *Corresponding author

14 **Futoshi Hasebe**

15 E-mail: rainbow@nagasaki-u.ac.jp

16

17

18

19

20

21

22

23

24

25

26 Abstract

27 Dengue encephalitis (DE) is characterized as unusual presentation of dengue infection.
28 Despite the reports that DE accounts for only 1% to 5% of dengue cases, this disease tends to
29 be increasingly reported to threaten global human health throughout dengue endemic areas
30 particularly in Southeast Asia. The molecular information of clinically characterized,
31 neurotropic dengue virus (DENV) in human beings is extremely scarce despite it playing an
32 important role in deciphering the pathogenesis of dengue-related neurological cases. Here we
33 report a case of DE caused by DENV3 genotype III in a male patient with atypical symptoms
34 of DENV infection in Hai Phong, Vietnam in 2013. The virus isolated from the cerebrospinal
35 fluid of this case-patient was closely related to DENV3 genotype III strains isolated from
36 serum of two other patients, who manifested classical dengue in the same year and residing in
37 the same area as the case-patient. It is noteworthy to mention that in 2013, DENV3 genotype
38 III was detected for the first time in Vietnam.

39

40

41

42

43

44

45

46

47

48

49

50

51 **1. Why this case is important**

52 Dengue virus (DENV) is a member of the family *Flaviviridae* consisting of
53 neurotropic viruses such as Japanese encephalitis virus, West Nile virus, St Louis encephalitis
54 virus and Murray Valley encephalitis virus. Unlike these pathogens, DENV rarely causes
55 neurologic symptoms (1). The early evidence of central nervous system (CNS) manifestations
56 associated with DENV infection was reported in several worldwide dengue outbreaks,
57 predominantly in endemic countries of Southeast Asia (1-6). These unusual presentations
58 have been classified as severe dengue cases (7) , however, the neuropathogenesis of DENV
59 infection is still poorly understood (8). Previously, neurologic manifestations were considered
60 as the consequences of an encephalopathy secondary to prolonged shock, hyponatraemia,
61 hepatic failure or intracranial bleeding rather than encephalitis because of the failure to
62 demonstrate the presence of DENV in the CNS (9, 10). Since the 1990s, the concept of
63 DENV neurotropism was noticed and the number of reports on dengue patients with virus
64 isolation from CSF or brain tissue has risen (10, 11). We hereby report a case of encephalitis
65 caused by DENV3 in a male patient with atypical symptoms of DENV infection in Hai
66 Phong, Vietnam. Virus isolation was achieved from CSF specimen. The complete envelope
67 (E) sequence of CSF-derived DENV3 isolated from this patient was explored to define
68 phylogenetic relationship with other DENV3 strains isolated from Hai Phong, Vietnam and
69 from neighboring countries. We noted that DENV3 genotype III was seen for the first time in
70 Vietnam in 2013.

71

72 **2. Case description**

73 A 25-year-old male, who worked as an accountant in Hai Phong, Vietnam, was
74 admitted to Viet Tiep's hospital on day 1 of the onset of illness due to high-grade fever and
75 severe headache. There was no myalgia, joint pain, diarrhea, skin and mucosal bleeding. The

76 patient did not have any past medical records indicating of DENV infection prior to this
77 event. On admission, general examination did not reveal any significant abnormalities.
78 Neurological examination did not show any focal neurological deficits apart from neck
79 stiffness. Laboratory tests showed normal range in hemogram with slight increase in C –
80 reactive protein (Table 1). CSF analysis revealed 10 white blood cells (WBC)/mm³ but there
81 was no information relating to protein, sugar and lactate (Table 1). A provisional diagnosis of
82 suspected meningoencephalitis was made and the patient was given an empiric antibiotic
83 treatment (Rocephin – the 3rd generation cephalosporin antibiotic) in view of the possibility
84 of bacterial infection. Despite this treatment, his symptoms were not improved, therefore, he
85 was transferred to the referral hospital on day 3 of disease onset. In this hospital, leukopenia
86 was noted in the laboratory tests; CSF analysis revealed 8 WBC/mm³ and slight increase in
87 protein concentration (Table 1). Treatment was continued with the 3rd generation of
88 cephalosporin antibiotic (Ceftriaxon) and analgesic. Occasionally, the patient was prescribed
89 with oral sedative (Seduxen) to control the irritation due to severe headache. On day 6 of
90 disease onset, hemogram showed continuous leukopenia associated with mild
91 thrombocytopenia and dengue serology (SD BIOLINE Dengue Duo kit) was positive for
92 anti-dengue IgM and IgG antibodies. Additionally, the patient started to feel improvement
93 from the symptoms of fever and headache simultaneous with the appearance of
94 maculopapular rash. On day 9 of disease onset, hemogram indicated a normalization of
95 leukocyte and platelet counts (Table 1). The patient was discharged after 9 days of
96 hospitalization without any neurological sequelae.

97 Following these results, a CSF specimen of this patient collected on day 1 of disease
98 onset in Viet tiep's hospital was retrospectively analyzed. In this CSF sample, although the
99 presence of anti-dengue IgM antibodies was negative by the in-house ELISA test, the
100 presence of DENV RNA was confirmed by reverse transcriptase polymerase chain reaction

101 (RT-PCR) and DENV3 was successfully isolated (Table 2). RNA sequence of this virus strain
102 was read by Ion Proton and 3100 Avant genetic analyzer (Life Technologies). Phylogenetic
103 analysis was conducted using the envelop protein coding region sequence with the two other
104 serum-derived DENV3 strains isolated in Hai Phong, Vietnam in 2013 and with other
105 DENV3 strains worldwide.

106

107 **3. Other similar and contrasting cases in literature**

108 Following the earliest evidence of CNS involvement associated with DENV infection
109 since 18th century (12), neurological cases due to DENV3 have been increasingly reported in
110 recent years worldwide (1, 5, 10, 13, 14). In the southern part of Vietnam, there was one
111 study that described the phylogenetic relationship between CSF-derived DENV2 and serum-
112 derived DENV2 from the same DE patient (14), however, there are no published data on
113 DENV3 genotype III infecting a patient with neurological manifestation.

114

115 **4. Discussion**

116 Dengue encephalitis has been noticed as an unusual presentation with the prevalence
117 being estimated to occur in 1% to 5% of dengue cases (8). Neurologic manifestations caused
118 by DENV can occur in a patient at the age of few months to 79 years and more frequently in
119 children (8). The median time for onset of CNS symptoms was reported to be 3 to 7 days
120 from the onset of fever (1, 4). Interestingly, Soares et al (2006) reported the existence of CNS
121 involvement for longer period ranging between 4 to 30 days with a median time of 12 days
122 after the onset of the fever among 13 patients aged 11 to 79 years (15). Surprisingly, the
123 presented case showed CNS symptoms on day 1 of the onset of fever.

124 In comparison to other dengue serotypes, DENV2 and DENV3 tend to have the highest
125 propensity to neurological complications whether in primary or secondary infections (1, 4).

126 Despite encephalitis being recognized as the most common presentation among patients
127 suffering neurological manifestations due to DENV infection, only 50% of these patients
128 present the typical features of DENV infection (8); thus the existence of underestimated
129 cases. Our patient from the beginning did not have any typical symptoms of dengue until the
130 hemogram from the referral hospital suggested DENV infection. However, CSF analysis
131 indicated viral infection at the early timing of disease course. Retrospective analysis of a CSF
132 specimen drawn on day 1 of fever onset was negative for anti-dengue IgM antibody by in-
133 house ELISA test. This result is acceptable because in serum specimens, IgM antibodies are
134 detectable by day 3-5 from the onset of illness in 50% of patients, increasing to 80% by day 5
135 and 99% by day 10 during primary infection and significantly lower in secondary infection
136 (7). Furthermore, data on ELISA test for dengue specific IgM antibodies revealed 46%
137 sensitivity in CSF of patients with neurological disorders, however, the absence of these
138 antibodies does not exclude dengue as the causative agent of CNS abnormalities (15). The
139 day for collecting CSF sample from this patient in the 1st hospital, i.e. day 1 from the onset of
140 the disease was too early to detect anti-dengue IgM antibodies in serum or in CSF, but it was
141 proper timing for virus isolation.

142 To isolate the virus, CSF specimen (10ul) was inoculated onto C6/36 mosquito cells
143 and Vero cells (African green monkey kidney). Cells were observed daily for cytopathic
144 effect (CPE) for seven days, RNA was extracted from culture fluid on day seven by using
145 QIAamp Viral RNA mini kit (QIAGEN) and the presence of DENV3 RNA was confirmed by
146 RT-PCR (Table 2) (16). The complete envelope nucleotide sequences of this isolate
147 (accession nos. KP893717) and the two serum-derived DENV3 isolates from different
148 patients with classical dengue fever in Hai Phong, Vietnam (accession nos. KP893718 and
149 KP893719) were determined and deposited in Genbank. Nucleotides sequences were aligned
150 by using MAFFT version 7.215 (17). The substitution models were selected by jmodeltest-

151 2.1.7 (18) and GTR+I+G was used as the model. Phylogenetic tree was constructed by
152 FigTree software, version 1.4.0. The envelope sequence of the three strains did not show any
153 difference in nucleotide and amino acid substitutions. However, the ongoing full genome
154 analysis showed Leu-3029-Phe and Thr-4077-Ile mutations in non-structural regions 1 and
155 2A (NS1& NS2A) sequences respectively in CSF derived DENV3 strain (data not shown).

156 Phylogenetic analysis showed the close relationship between this CSF-derived
157 DENV3 and the two serum-derived DENV3 strains and all of them were isolated from
158 different patients in Hai phong, Vietnam in 2013 and were determined to belong to genotype
159 III (Figure 1). Previously, genotype II had been circulating in Vietnam (Figure 1). DENV3
160 genotype III was reported to be continuously circulating in the Indian subcontinent since the
161 1960s (19). Since 2005, this genotype III of DENV3 was increasingly found in Bhutan,
162 Thailand, Laos, Cambodia, Pakistan, China, Senegal and Côte d'Ivoire (19-22) (Figure 1). To
163 our knowledge, this is the first report describing the emergence of DENV3 genotype III in
164 Vietnam in 2013.

165 In conclusion, dengue encephalitis is a rarely reported infection, however, its
166 detection tends to increase the threat to global human health. Despite the unusual
167 manifestations and challenges in diagnosis, DE should be investigated further in all patients
168 with encephalitis regardless of the absence of classical dengue features.

169

170 **Funding:**

171 This work was funded by the Grant-in-Aid for Scientific Research (KAKENHI No.
172 24659210); Global Center of Excellence Program, Ministry of Education, Culture, Sports,
173 Science and Technology, Japan; e-Asia Joint Research Program, Japan Science and
174 Technology Agency (JST), Japan; Japan Initiative for Global Research Network on
175 Infectious Diseases; Research on Emerging and Re-emerging Infectious Diseases, JST, Japan

176 (H23-shinkou-ippan-010); and grant(s) in aid for scientific research by the Ministry of Health,
177 Labour and Welfare, Japan.

178 **Competing interests:**

179 The authors have declared that no competing interests exist.

180 **Ethical approval:**

181 This study was approved by the Institutional Review Board of NIHE, Vietnam (No.15-HDD,
182 January 18, 2011).

183 **Acknowledgements**


184 We thank Dr. Ngo Chi Cuong of the Department of Internal Medicine, Institute of Tropical
185 Medicine, Nagasaki, Japan and Bach Mai Hospital, Hanoi, Vietnam for helping in the
186 collection of clinical data. We thank Dr. Mya Myat Ngwe Tun, Dr. Leo Uchida and Mr.
187 Adung'o Ferdinard, who are all members of the Department of Virology, Institute of Tropical
188 Medicine, Nagasaki University, Nagasaki, Japan for providing technical advice. This research
189 is partially supported by from Japan Agency for Medical Research and development, AMED.

190 **References**

- 191 1. Cam BV, Fonsmark L, Hue NB, Phuong NT, Poulsen A, Heegaard ED. Prospective
192 case-control study of encephalopathy in children with dengue hemorrhagic fever. *Am J Trop*
193 *Med Hyg.* 2001 Dec;65(6):848-51.
- 194 2. Ramos C, Sanchez G, Pando RH, Baquera J, Hernandez D, Mota J, et al. Dengue
195 virus in the brain of a fatal case of hemorrhagic dengue fever. *J Neurovirol.* 1998
196 Aug;4(4):465-8.
- 197 3. Pancharoen C, Thisyakorn U. Neurological manifestations in dengue patients.
198 *Southeast Asian J Trop Med Public Health.* 2001 Jun;32(2):341-5.
- 199 4. Samanta M, Kundu CK, Guha G, Chatterjee S. Unique neurological manifestations of
200 dengue virus in pediatric population: a case series. *J Trop Pediatr.* 2012 Oct;58(5):398-401.

- 201 5. Tahir M, Gupta E, Salmani S, Padma MV, Singh MB, Dar L, et al. Dengue fever with
202 papilledema: a case of dengue-3 virus infection in central nervous system. *J Clin Virol.* 2006
203 Sep;37(1):65-7.
- 204 6. Le VT, Phan TQ, Do QH, Nguyen BH, Lam QB, Bach V, et al. Viral etiology of
205 encephalitis in children in southern Vietnam: results of a one-year prospective descriptive
206 study. *PLoS neglected tropical diseases.* 2010;4(10):e854.
- 207 7. World Health Organisation. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control* 2009: Who
208 Health Organisation 2009.
- 209 8. Puccioni-Sohler M, Rosadas C, Cabral-Castro MJ. Neurological complications in
210 dengue infection: a review for clinical practice. *Arq Neuropsiquiatr.* 2013 Sep;71(9b):667-71.
- 211 9. Carod-Artal FJ, Wichmann O, Farrar J, Gascon J. Neurological complications of
212 dengue virus infection. *Lancet Neurol.* 2013 Sep;12(9):906-19.
- 213 10. Lum LC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity?
214 *Am J Trop Med Hyg.* 1996 Mar;54(3):256-9.
- 215 11. Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, Levi JE, Pannuti CS.
216 Involvement of the central nervous system in patients with dengue virus infection. *J Neurol*
217 *Sci.* 2008 Apr 15;267(1-2):36-40.
- 218 12. Lam SK. Dengue infections with central nervous system manifestations. *Neurological*
219 *Journal Southeast Asia.* 1996;1:3-6.
- 220 13. Soares CN, Cabral-Castro MJ, Peralta JM, Freitas MR, Puccioni-Sohler M.
221 Meningitis determined by oligosymptomatic dengue virus type 3 infection: report of a case.
222 *Int J Infect Dis.* 2010 Feb;14(2):e150-2.
- 223 14. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al.
224 Neurological manifestations of dengue infection. *Lancet.* 2000 Mar 25;355(9209):1053-9.
- 225 15. Soares CN, Faria LC, Peralta JM, de Freitas MR, Puccioni-Sohler M. Dengue

- 226 infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. *J Neurol Sci.*
227 2006 Nov 1;249(1):19-24.
- 228 16. Pandey BD, Nabeshima T, Pandey K, Rajendra SP, Shah Y, Adhikari BR, et al. First
229 isolation of dengue virus from the 2010 epidemic in Nepal. *Trop Med Health. Japan*; 2013.
230 p. 103-11.
- 231 17. Katoh K, Kuma K, Miyata T, Toh H. Improvement in the accuracy of multiple
232 sequence alignment program MAFFT. *Genome Inform. Japan*; 2005. p. 22-33.
- 233 18. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new
234 heuristics and parallel computing. *Nat Methods. United States*; 2012. p. 772.
- 235 19. Sun J, Lin J, Yan J, Fan W, Lu L, Lv H, et al. Dengue virus serotype 3 subtype III,
236 Zhejiang Province, China. *Emerg Infect Dis.* 2011 Feb;17(2):321-3.
- 237 20. Fatima Z, Idrees M, Bajwa MA, Tahir Z, Ullah O, Zia MQ, et al. Serotype and
238 genotype analysis of dengue virus by sequencing followed by phylogenetic analysis using
239 samples from three mini outbreaks-2007-2009 in Pakistan. *BMC Microbiol.* 2011;11:200.
- 240 21. Faye O, Ba Y, Talla C, Diallo D, Chen R, Mondo M, et al. Urban epidemic of dengue
241 virus serotype 3 infection, Senegal, 2009. *Emerg Infect Dis.* 2014 Mar;20(3):456-9.
- 242 22. Luo L, Liang HY, Jing QL, He P, Yuan J, Di B, et al. Molecular characterization of the
243 envelope gene of dengue virus type 3 newly isolated in Guangzhou, China, during 2009-
244 2010. *Int J Infect Dis.* 2013 Jul;17(7):e498-504.
- 245
- 246



Genotype III

Genotype I

Genotype II

Genotype IV

Figure 1: ML-phylogenetic tree based on the envelope gene sequence of DENV3 isolates. The envelope sequence of DENV3 (CSF11098) isolated from the CSF of our case-patient in Hai Phong, Vietnam in 2013 was compared with those of DENV3 (5228 NGS and 5468 NGS) isolated from serum samples of other patients in the same place and in the same year. The strain names of these three DENV3 isolates were enclosed in red square. This fragment of CSF derived DENV3 was also compared with others homologous sequences of DENV3 in GenBank database from different geographical regions. Bootstrap values over 800 > of 1000 repeats are shown at the nodes. Labels of strains conform to the following format: (GenBank accession nos)_(Strain name)_(Country-region)_(Year of isolation).

Table 1: Summary of laboratory analysis during admission

Hospital	Viet tiep's hospital		Referral hospital	
Day of onset	1	3	6	9
Hemogram				
– <i>WBC</i> ($\times 10^3/\text{ul}$)	5.7	2.72	2.09	5.28
– <i>Hb</i> (g/dl)	11.4	12.5	13	12.9
– <i>Hct</i> (%)	34.5	36.7	39	38.3
– <i>PLT</i> ($\times 10^3/\text{ul}$)	274	220	128	201
CRP (mg/l)	12	0.79	ND	ND
AST (U/l)	40	55	ND	ND
ALT (U/l)	28	50	ND	ND
Dengue serology test				
– <i>Anti – dengue IgM antibody</i>	ND	ND	Pos	ND
– <i>Anti – dengue IgG antibody</i>	ND	ND	Pos	ND
CSF analysis				
– <i>WBC/mm³</i>	10 ^(*)	8	ND	ND
– <i>Protein</i> (g/l)	ND	0.46	ND	ND
– <i>Glucose</i> (mmol/l)	ND	5.2	ND	ND
– <i>Gram staining</i>	ND	Neg	ND	ND
– <i>Bacterial isolation</i>	ND	Neg	ND	ND

WBC: white blood cells; Hb: Hemoglobin; Hct: Hematocrit; PLT: platelet; CRP: C-reactive protein (normal range: <0.5mg/dl); AST: aspartate transaminase (normal range: <37 U/l); ALT: alanine transaminase (normal range: <41 U/l); CSF: cerebral spinal fluid; Pos: positive; Neg:

negative; ND: not done

(*): 60% polymorphs and 40% lymphocytes

Table 2: Primers use for RT-PCR and amplification of DENV3 envelope gene.

Primer name	Reaction	sense	Sequence (5'-3')
Random primer	RT-PCR	-	
VNR primer	RT-PCR	-	AGAACCTGTTGATTCAACAGCACCATTC
DENV-consensus	PCR	F	TCAATATGCTGAAACGCGCGAGAAACCG
DENV-consensus	PCR	R	TTGCACCAACAGTCAATGTCTTCAGGTTC
DENV-3-specific	PCR	F	GTGCTTACACAGCCCTATTT
DENV-3-specific	PCR	R	TCCATTCTCCAAGCGCCTG

RT-PCR: reverse transcriptase-polymerase chain reaction; F: forward; R: reverse; DENV:

dengue virus.